{"id":"placebo-omeprazole-or-rabeprazole-clarithromycin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"1-5%","effect":"Clarithromycin: QT interval prolongation"}]},"_chembl":{"chemblId":"CHEMBL1219","moleculeType":"Small molecule","molecularWeight":"359.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Omeprazole and Rabeprazole work by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, resulting in a decrease in gastric acid secretion. Clarithromycin, on the other hand, binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis and ultimately leading to bacterial cell death.","oneSentence":"Omeprazole and Rabeprazole are proton pump inhibitors that reduce gastric acid secretion, while Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:18.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Eradication of Helicobacter pylori in patients with peptic ulcer disease"},{"name":"Treatment of gastroesophageal reflux disease (GERD)"}]},"trialDetails":[{"nctId":"NCT02407119","phase":"PHASE3","title":"Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2003-06","conditions":"Helicobacter Pylori Infection, Early Gastric Cancer, Endoscopic Resection","enrollment":470},{"nctId":"NCT01002443","phase":"PHASE2","title":"Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2003-07","conditions":"Gastric Cancer","enrollment":190}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1005,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo, Omeprazole or Rabeprazole, Clarithromycin","genericName":"Placebo, Omeprazole or Rabeprazole, Clarithromycin","companyName":"National Cancer Center, Korea","companyId":"national-cancer-center-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omeprazole and Rabeprazole are proton pump inhibitors that reduce gastric acid secretion, while Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. Used for Eradication of Helicobacter pylori in patients with peptic ulcer disease, Treatment of gastroesophageal reflux disease (GERD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}